Added to YB: 2026-01-15
Pitch date: 2026-01-13
ARGX [neutral]
argenx SE
-0.58%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 48.0B
Pitch Price
EUR 694.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
61.64
P/E
33.71
EV/Sales
11.98
Sector
Biotechnology
Category
growth
Argenx (ARGX Belgium): from blockbuster execution to platform ambition
ARGX (update): VYVGART crossed blockbuster territory w/ $4.1B 2025 sales (nearly 2x YoY) driven by gMG & CIDP uptake. Expanding addressable population via new indications (seronegative/ocular MG, ITP, myositis, Sjögren's). 10 registrational studies ongoing, targeting 10 molecules in dev by 2026.
Read full article (2 min)